A Phase III Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an ART Regimen, Including TMC114/RTV and an Investigator-Selected OBR, in HIV-1 Infected Patients With Limited Treatment to No Treatment Options.

Trial Profile

A Phase III Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an ART Regimen, Including TMC114/RTV and an Investigator-Selected OBR, in HIV-1 Infected Patients With Limited Treatment to No Treatment Options.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Etravirine (Primary) ; Darunavir; Enfuvirtide; Nucleoside reverse transcriptase inhibitors; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms DUET-2
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 27 Aug 2010 Pooled 96-week tolerability results from DUET-1 and DUET-2 have been published in the Journal of Antimicrobial Chemotherapy.
    • 01 Jan 2010 Pooled 96-week efficacy and tolerability results from DUET-1 and DUET-2 have been published in Antiviral Therapy.
    • 11 Nov 2009 Pooled 96-week tolerability results from DUET-1 and -2 were presented at EACS 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top